Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

February 15, 2023

Pirtobrutinib was generally well-tolerated, and most patients did not experience high-grade recurrence of the adverse event that led to discontinuation of the prior covalent Bruton tyrosine kinase inhibitor (BTKi). Pirtobrutinib may be an important option to extend the benefit of BTK inhibition among patients who could not tolerate previous
MS-553, a protein kinase C-beta (PKCß) inhibitor, is an exciting new agent in a yet-to-be-approved class of drugs that target an area of the B-cell receptor pathway independent of Bruton tyrosine kinase (BTK) and phospholipase C gamma 2 (PLCy2) mutations which confer resistance to BTK inhibitors.